H.R. 7083, entitled the “Access to Genetic Counselor Services Act of 2018,” is cosponsored by Congressmen Erik Paulsen (R-Minn.) and Dave Loebsack (D-Iowa), and was developed in collaboration with the National Society of Genetic Counselors. The goal is to add genetic counselors as qualified Medicare providers, so they can receive payment for counseling Medicare beneficiaries. In addition, genetic counselors could see Medicare beneficiaries without supervision. This will create consistency between state licensure and CMS policy.
Currently, certified genetic counselors are not recognized by Centers for Medicare & Medicaid Services even though genetic counseling is a covered benefit under Medicare. However, genetic counselors play an integral role in patient care by helping individuals understand the diseases that affect them and their families, by interpreting genetic test results, and by explaining how those results may guide prevention and treatment options. While access to genetic counseling remains an issue due to the inadequate number of certified genetic counselors, there is the possibility that passage of this bill could reduce unnecessary spending on inappropriate genetic tests ordered by providers who may lack genetic expertise, thereby improving patient care.
115TH CONGRESS 2D SESSION H. R. 7083: To amend title XVIII of the Social Security Act to provide for expanded coverage of services furnished by genetic counselors under part B of the Medicare program, and for other purposes. (October 2018)
Please log in to access ObGFirst and the 2T US Atlas
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst